Avenue Therapeutics annual ebitda
2022
2023
2024
2025
Avenue Therapeutics EBITDA Growth & History (ATXI)
Avenue Therapeutics's calculated EBITDA was −$3.3M for fiscal 2025.
View full Avenue Therapeutics company overviewAvenue Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$3.3M | $8.0M | — |
| 2024 | 2024-12-31 | −$11.3M | −$1.1M | — |
| 2023 | 2023-12-31 | −$10.2M | −$7.7M | — |
| 2022 | 2022-12-31 | −$2.4M | — | — |
Avenue Therapeutics quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$707,000 | −$1.0M | — |
| Q1 2026 | 2026-03-31 | −$714,000 | — | — |
| Q4 2025 | 2025-12-31 | −$955,000 | — | — |
| Q3 2025 | 2025-09-30 | −$724,000 | — | — |
| Q2 2025 | 2025-06-30 | $297,000 | — | — |
Avenue Therapeutics ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Avenue Therapeutics's ebitda decreased from −$2.4M to −$3.3M, a change of −$843,000. The latest reported quarter, Q2 2026, shows −$707,000.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Avenue Therapeutics source filings ↗